Treatment with anti-MHC-class-II antibody postpones kidney allograft rejection in primates but increases the risk of CMV activation

American Journal of Transplantation

Volumn 4, Issue 11, 2004, Pages 1756-1761

  Jonker, Margreet ^a   Ringers, Jan ^b   Kuhn, Eva Maria ^a,c   Hart, Bert't ^a   Foulkes, Roland ^d  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c INTERVET INTERNATIONAL BV   (Netherlands)

^d UCB PHARMA   (Belgium)

Author keywords

CMV; Kidney transplantation; MHC class II antibody

Indexed keywords

ANTIBODY; CDP 855; HLA DR ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2 ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; GRAFT REJECTION; KIDNEY TRANSPLANTATION; MONKEY; NONHUMAN; PRIMATE; PRIORITY JOURNAL; VIRUS ACTIVATION;

ANIMALS; ANTIBODIES; CYTOMEGALOVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS II; KIDNEY TRANSPLANTATION; MACACA FASCICULARIS; POSTOPERATIVE COMPLICATIONS;

EID: 2942550212     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00589.x     Document Type: Article

References (35)

1. Thomas JM, Eckhoff DE, Contreras JL et al. Durable donor-specific T and B cell tolerance in rhesus macaques induced with peritransplantation anti-CD3 immunotoxin and deoxyspergualin: Absence of chronic allograft nephropathy. Transplantation 2000; 69: 2497-2503.
2. Knechtle SJ, Vargo D, Fechner J et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 1997; 63: 1-6.
3. Sachs DH. Mixed chimerism as an approach to transplantation tolerance. Clin Immunol 2000; 95: S63-S68.
4. Kirk AD, Burkly LC, Batty DS et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5: 686-693.
5. Hart DN, Fabre JW. Passive enhancement of rat renal allografts using mouse monoclonal xenoantibodies. Transplantation 1981; 32: 431-436.
6. Kruisbeek AM, Bridges S, Carmen J, Longo DL, Mond JJ. In vivo treatment of neonatal mice with anti-I-A antibodies interferes with the development of the class I, class II, and MIs-reactive proliferating T cell subset. J Immunol 1985; 134: 3597-3604.
7. McDevitt HO, Perry R, Steinman LA. Monoclonal anti-la antibody therapy in animal models of autoimmune disease. Ciba Found Symp 1987; 129: 184-193.
8. Priestley CA, Spencer SC, Sawyer GJ, Fabre JW. Suppression of kidney allograft rejection across full MHC barriers by recipient-specific antibodies to class II MHC antigens. Transplantation 1992; 53: 1024-1032.
9. Saxton NE, Hallaway RV, Ladyman HM et al. Anti-major histocompatibility complex class II treatment prevents graft rejection in the hamster-to-rat cardiac xenograft. Transplantation 1999; 67: 1599-1606.
10. Smith RM, Chen ZK, Foulkes R, Metcalfe SM, Wraith DC. Prolongation of murine vascularized heart allograft survival by recipient-specific anti-major histocompatibility complex class II antibody. Transplantation 1997; 64: 525-528.
11. Foulkes R. Preclinical safety evaluation of monoclonal antibodies. Toxicology 2002; 174: 21-26.
12. Chatterjee SN, Billings R, Bernoco D, Terasaki P. Early evaluation of la monoclonal antibodies in prolonging non-human primate skin allograft survival. Proc Eur Dial Transplant Assoc 1981; 18: 362-366.
13. Chatterjee S, Bernoco D, Billing R. Treatment with anti-la and antiblast/monocyte monoclonal antibodies can prolong skin allograft survival in nonhuman primates. Hybridoma 1982; 1: 369-377.
14. Jonker M, Nooij FJ, den Butter G, van Lambalgen R, Fuccello AJ. Side effects and immunogenicity of murine lymphocyte-specific monoclonal antibodies in subhuman primates. Transplantation 1988; 45: 677-682.
15. Jonker M, van Lambalgen R, Mitchell DJ, Durham SK, Steinman L. Successful treatment of EAE in rhesus monkeys with MHC class II specific monoclonal antibodies. J Autoimmun 1988; 1: 399-414.
16. Bontrop RE, Otting N, Slierendregt BL, Lanchbury JS. Evolution of major histocompatibility complex polymorphisms and T-cell receptor diversity in primates, Immunol Rev 1995; 143: 33-62.
17. Doxiadis GG, Otting N, Antunes SG et al. Characterization of the ABO blood group genes in macaques: Evidence for convergent evolution. Tissue Antigens 1998; 51: 321-326.
18. Barclay NA, Birkeland ML, Brown MH et al. The Leucocyte Antigen Facts Book. Academic Press: New York, 1993.
19. Neuhaus P, Neuhaus R, Wiersema HD, Borleffs JC, Balner H. The technique of kidney transplantation in rhesus monkeys. J Med Primatol 1982; 11: 155-162.
20. Ossevoort MA, Ringers J, Kuhn EM et al. Prevention of renal allograft rejection in primates by blocking the B7/CD28 pathway. Transplantation 1999; 68: 1010-1018.
21. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
22. Morgan A, Jones ND, Nesbitt AM, Chaplin L, Bodmer MW, Emtage JS. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding. Immunology 1995; 86: 319-324.
23. Schuurman HJ, Ringers J, Schuler W, Slingerland W, Jonker M. Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation. Transplantation 2000; 69: 737-742.
24. van Rood JJ, van Leeuwen A, Termijtelen A, Keuning JJ. B-cell antibodies, la-like determinants, and their relation to MLC determinants in man. Transplant Rev 1976; 30: 122-139.
25. Jonker M, van Meurs G, Bainer H. Typing for RhLA-D in rhesus monkeys: I. Characteristics of ten groups of homozygous typing cells. Tissue Antigens 1982; 19: 60-68.
26. Steel CM, Van Heyningen V, Guy K, Cohen BB, Deane DL. Influence of monoclonal anti-Ia like antibodies on activation of human lymphocytes. Immunology 1982; 47: 597-603.
27. Effros RB, Hulette CM, Ettenger R et al. A human-human hybridoma secreting anti-HLA class II antibody. J Immunol 1986; 137: 1599-603.
28. Kalil J, Wollman EE. Role of class I and class II antigens in the allogenic stimulation: Class I and class II recognition in allogenic stimulation; blocking of MLR by monoclonal antibodies and F(ab')2 fragments. Cell Immunol 1983; 79: 367-373.
29. Shapiro ME, Liu M, Smith R, Saxton NE, Nesbitt AM, Foulkes R. Anti-MHC class II Mabs suppress allogeneic responses in solid organ transplantation in mice and primates. Transplantation 1998; 65: 377.
30. Jonker M. The importance of non-human primates for preclinical testing of immunosuppressive monoclonal antibodies. Semin Immunol 1990; 2: 427-436.
31. Kuhn EM, Stolte N, Matz-Rensing K et al. Immunohistochemical studies of productive rhesus cytomegalovirus infection in rhesus monkeys (Macaca mulatta) infected with simian immunodeficiency virus. Vet Pathol 1999; 36: 51-56.
32. Hummel M, Abecassis MM. A model for reactivation of CMV from latency. J Clin Virol 2002; 25(Suppl 2): S123-S136.
33. Bumgardner GL, Orosz CG. Transplantation and cytokines. Semin Liver Dis 1999; 19: 189-204.
34. Coral S, Pucillo C, Leonardi A, Fonsatti E, Altomonte M, Maio M. Triggering of HLA-DR antigens differentially modulates tumor necrosis factor alpha release by B cells at distinct stage of maturation. Cell Growth Differ 1997; 8: 581-588.
35. Leonardi A, Altomonte M, Maio M et al. Biphasic control of NF-kappa B activation induced by the triggering of HLA-DR antigens expressed on B cells. Cytokine 1997; 9: 295-299.